Your browser is no longer supported. Please, upgrade your browser.
CANF Can-Fite BioPharma Ltd. daily Stock Chart
CANF [NYSE]
Can-Fite BioPharma Ltd.
Index- P/E- EPS (ttm)-0.30 Insider Own- Shs Outstand34.73M Perf Week-6.98%
Market Cap41.67M Forward P/E- EPS next Y-0.19 Insider Trans- Shs Float11.93M Perf Month-6.25%
Income- PEG- EPS next Q0.00 Inst Own19.57% Short Float3.10% Perf Quarter-9.77%
Sales1.40M P/S29.67 EPS this Y67.70% Inst Trans- Short Ratio1.38 Perf Half Y-44.70%
Book/sh0.43 P/B2.78 EPS next Y-90.00% ROA- Target Price8.00 Perf Year-24.05%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.12 - 2.75 Perf YTD-18.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.36% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.14% ATR0.06
Employees7 Current Ratio- Sales Q/Q730.00% Oper. Margin- RSI (14)46.81 Volatility5.64% 4.17%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close1.20
ShortableYes LT Debt/Eq- EarningsAug 31 BMO Payout- Avg Volume268.42K Price1.20
Recom2.00 SMA20-2.20% SMA50-3.26% SMA200-19.98% Volume10,170 Change0.00%
Aug-11-17Initiated Maxim Group Buy $7
Oct-19-16Resumed ROTH Capital Buy
Aug-29-16Resumed Rodman & Renshaw Buy $6
Nov-30-15Reiterated H.C. Wainwright Buy $4 → $6
Mar-31-15Reiterated H.C. Wainwright Buy $7 → $3
Mar-30-15Downgrade ROTH Capital Buy → Neutral $20 → $2.40
Dec-29-14Reiterated ROTH Capital Buy $28 → $20
Nov-18-14Initiated H.C. Wainwright Buy $7
Aug-07-18 09:14AM  Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China Business Wire -5.43%
Aug-06-18 05:54AM  Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical Business Wire +10.26%
05:19AM  BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement Reuters
Jul-17-18 08:56AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug Business Wire
Jul-02-18 09:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer Business Wire
Jun-19-18 07:00AM  Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial Business Wire +8.13%
Jun-13-18 08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson Business Wire
Jun-01-18 07:00AM  Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update Business Wire +6.37%
Apr-25-18 07:00AM  Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research' Business Wire
Apr-13-18 07:30AM  Wired News CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018 ACCESSWIRE
Apr-09-18 07:00AM  Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) Business Wire
Mar-28-18 07:00AM  Can-Fite to Present at the MicroCap Conference Business Wire
Mar-23-18 07:00AM  Can-Fite Reports 2017 Financial Results & Provides Clinical Update Business Wire
Mar-14-18 07:00AM  Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference Business Wire
Mar-09-18 09:00AM  Can-Fite BioPharma Announces $5 Million Registered Direct Offering Business Wire -19.55%
Mar-06-18 07:00AM  Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference Business Wire
Mar-05-18 07:00AM  Can-Fite to Present at the Inaugural LD Micro Virtual Conference Business Wire
Feb-28-18 09:25AM  Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson Business Wire +6.21%
Feb-22-18 08:00AM  Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile Business Wire -5.46%
Feb-12-18 07:00AM  Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson Business Wire +7.43%
Jan-31-18 07:00AM  Can-Fite to Present at BIO CEO & Investor Conference Business Wire
Jan-25-18 07:00AM  Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries Business Wire +18.42%
Jan-11-18 07:00AM  Can-Fite 12 Months' Activities & Milestones for 2018 Business Wire -5.70%
Jan-08-18 07:40AM  Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings Business Wire +6.41%
Jan-03-18 07:00AM  Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Business Wire
Dec-25-17 09:17AM  Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-18-17 07:00AM  Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson Business Wire +13.85%
Dec-13-17 07:50AM  Wired News ADMA Files Biologics License Application for Its Third Plasma Collection Center ACCESSWIRE
Nov-27-17 07:30AM  Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update Business Wire
07:00AM  Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson Business Wire
Nov-17-17 07:00AM  Can-Fites Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma Business Wire
Oct-30-17 09:50AM  Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis Business Wire
Oct-17-17 07:00AM  Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis Business Wire
Oct-16-17 07:00AM  Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C. Business Wire
Oct-09-17 07:00AM  Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017 Business Wire
Oct-06-17 09:08AM  Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-25-17 07:00AM  Earnings Review and Free Research Report: Can-Fites Revenue Increased 25% ACCESSWIRE
Sep-18-17 07:00AM  Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy Business Wire
Sep-01-17 07:00AM  Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update Business Wire +7.19%
Aug-25-17 07:50AM  Featured Company News Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea ACCESSWIRE
Aug-23-17 07:00AM  Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea Business Wire
Aug-09-17 07:00AM  Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer Business Wire
Aug-07-17 07:00AM  Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson Business Wire -7.56%
Jul-17-17 07:00AM  Can-Fites Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting Business Wire
Jun-15-17 07:00AM  Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017 PR Newswire
Jun-08-17 07:00AM  Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis PR Newswire
Jun-05-17 07:00AM  Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH PR Newswire
Jun-01-17 07:00AM  New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017 PR Newswire +5.65%
May-30-17 07:00AM  Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update PR Newswire
May-16-17 07:00AM  Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study PR Newswire
May-03-17 07:00AM  Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH PR Newswire
Apr-25-17 07:00AM  Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board PR Newswire
Mar-31-17 07:00AM  Can-Fite Reports 2016 Financial Results & Provides Clinical Update PR Newswire
Feb-28-17 07:00AM  New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis PR Newswire
Feb-23-17 11:00AM  CANF: Ready to Start Two Phase III Trials in 2017 Zacks Small Cap Research
Feb-08-17 07:00AM  Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis PR Newswire
Jan-19-17 07:29AM  Can-Fite BioPharma Announces $5 Million Registered Direct Offering PR Newswire -8.00%
Jan-09-17 07:00AM  Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017 PR Newswire
Dec-21-16 07:00AM  Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea PR Newswire
Dec-16-16 07:00AM  New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH PR Newswire +8.88%
Nov-25-16 07:00AM  Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update PR Newswire +7.87%
Nov-16-16 07:00AM  American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102 PR Newswire
Nov-09-16 07:00AM  Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug PR Newswire +5.16%
Nov-07-16 07:00AM  Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany PR Newswire
Nov-01-16 07:00AM  Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA PR Newswire
Oct-25-16 07:15AM  Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea PR Newswire
Oct-14-16 12:36PM  Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF) at Investopedia
Oct-13-16 07:00AM  Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH PR Newswire
Sep-20-16 08:26PM  Positive Data on Liver Cancer Drug (CANF) at Investopedia +5.88%
07:00AM  Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal PR Newswire
Sep-15-16 11:04AM  Can-Fite Secures Patent for Psoriasis Treatment at Investopedia
Sep-13-16 07:00AM  Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial PR Newswire
Sep-07-16 07:00AM  Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016 PR Newswire
Aug-26-16 07:00AM  Can-Fite Reports Financial Results for Six Months Ended June 30, 2016 PR Newswire
Aug-24-16 01:45PM  Can-Fite (CANF): Update on its Clinical Programs
Aug-08-16 07:00AM  Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology PR Newswire
Jul-25-16 07:00AM  Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD PR Newswire
Jul-05-16 07:00AM  OphthaliX Announces Phase II Glaucoma Data PR Newswire
Jun-15-16 07:00AM  Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects PR Newswire
Jun-07-16 07:00AM  Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) PR Newswire
Jun-03-16 01:50PM  Can-Fite to Exhibit at Bio International Convention in San Francisco on June 6-9, 2016 PR Newswire
Jun-01-16 03:11PM  CANF: Update on First Quarter Financials ended March 31, 2016
07:00AM  Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis PR Newswire
May-27-16 07:00AM  Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update PR Newswire
May-02-16 07:00AM  Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association's Annual Meeting PR Newswire
Apr-29-16 07:00AM  Can-Fite to Present at Joseph Gunnar & Co.'s Pioneers 2016 Conference in New York City on May 5, 2016 PR Newswire
Apr-11-16 05:13PM  LifeSci Capital Initiates Coverage of Can-Fite BioPharma Accesswire
01:56PM  What Has Investors Excited About These 5 Stocks Today? at Insider Monkey
10:31AM  Why Are These 4 Stocks So Volatile Today? Accesswire
07:00AM  Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose PR Newswire
Apr-07-16 01:04PM  CAN-FITE BIOPHARMA LTD. Financials
Apr-04-16 11:30AM  CANF: Can-Fite Exited 2015 with a Strong Balance Sheet
07:00AM  Can-Fite to Participate in BIO-Europe Partnering Conference on April 4-6, 2016 in Stockholm, Sweden PR Newswire
Apr-01-16 07:00AM  Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update PR Newswire
Mar-17-16 07:00AM  Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis PR Newswire
Mar-16-16 11:45AM  CANF: Many Catalysts for 2016
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.